Status:
Concluded with an LOI
Manufacturer:
Medison Pharma Canada Inc.
Indication:
Pruritus in patients aged 6 months or older with progressive familial intrahepatic cholestasis (PFIC).
Last updated August 6, 2025
Status:
Concluded with an LOI
Manufacturer:
Astellas Pharma Inc.
Indication:
In combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumours are Claudin (CLDN) 18.2 positive
Last updated July 31, 2025
Casgevy (exagamglogene autotemcel)
Status:
Active negotiation
Manufacturer:
Vertex Pharmaceuticals (Canada) Incorporated
Indication:
Sickle cell disease
Last updated July 29, 2025
Casgevy (exagamglogene autotemcel)
Status:
Active negotiation
Manufacturer:
Vertex Pharmaceuticals (Canada) Incorporated
Indication:
Transfusion-dependent ?-thalassemia
Last updated July 29, 2025
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
In combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
Last updated July 24, 2025
Status:
Concluded with an LOI
Manufacturer:
Kyowa Kirin Canada, Inc.
Indication:
X-Linked Hypophosphatemia
Last updated July 21, 2025
Status:
Concluded with an LOI
Manufacturer:
Celltrion Healthcare Canada Ltd.
Indication:
Multiple Indications
Last updated July 14, 2025
Status:
Concluded with an LOI
Manufacturer:
Ultragenyx Pharmaceutical Inc.
Indication:
Homozygous Familial Hypercholesterolemia
Last updated July 8, 2025
Status:
Negotiations were not pursued
Manufacturer:
Sun Pharma Canada Inc.
Indication:
Acne Vulgaris
Last updated July 4, 2025
Status:
Concluded with an LOI
Manufacturer:
Alexion Pharma GmbH
Indication:
Generalized myasthenia gravis (gMG)
Last updated July 3, 2025